Germany’s Parkinson’s Disease Treatment market size stood at around USD XX.X billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of around XX.X% during the forecast period.
Parkinson’s disease (PD) is the second most common neurodegenerative disorder at higher ages (50+), causing disability and care dependency with increasing duration. With aging populations, the number of individuals affected by this incurable disease will almost double in Europe with Germany having its major share.
Understanding of treatment, increased expenditure on research and development, favorable drug reimbursement regulations and policies, high incidence of Parkinson’s disease, the rapid increase in the elderly population, and potential medical pipeline products may account for a significant share of the Parkinson’s disease treatment market.
Germany Parkinson’s Disease market propels with a growing public understanding of this disease, the multiplying elderly population, the prospect of launching pipeline drugs and new products, and relatively high growth in the therapeutic market.
The government and non-profit organizations’ understanding of Parkinson’s disease and higher clinical research and development budgets are expected to drive the growth of the Parkinson’s disease market over the forecast period. However, it is expected that the patent expiry of crucial drugs and side effects related to therapeutic medicines might limit the growth.